Saini Kamal S, Martins-Branco Diogo, Tagliamento Marco, Vidal Laura, Singh Navneet, Punie Kevin, Saini Monika Lamba, Chico Isagani, Curigliano Giuseppe, de Azambuja Evandro, Lambertini Matteo
Covance Inc, Princeton, NJ, USA.
, 77 Avenue Marcel Thiry, 1200, Brussels, Belgium.
Oncol Ther. 2021 Dec;9(2):255-265. doi: 10.1007/s40487-021-00157-1. Epub 2021 Jun 16.
Coronavirus disease 2019 (COVID-19) has resulted in millions of deaths globally. The pandemic has had a severe impact on oncology care and research. Patients with underlying cancer are more vulnerable to contracting COVID-19, and also have a more severe clinical course following the infection. The rollout of COVID-19 vaccines in many parts of the world has raised hopes of controlling the pandemic. In this editorial, the authors outline key characteristics of the currently approved COVID-19 vaccines, provide a brief overview of key emerging issues such as vaccine-induced immune thrombotic thrombocytopenia and SARS-CoV-2 variants of concern, and review the available data related to the efficacy and side effects of vaccinating patients with cancer.
2019年冠状病毒病（COVID-19）已在全球造成数百万人死亡。这场大流行对肿瘤护理和研究产生了严重影响。患有基础癌症的患者更容易感染COVID-19，并且在感染后临床病程也更严重。世界许多地区推出COVID-19疫苗带来了控制大流行的希望。在这篇社论中，作者概述了目前已获批的COVID-19疫苗的关键特征，简要介绍了诸如疫苗诱导的免疫性血栓性血小板减少症和值得关注的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体等关键新出现问题，并回顾了与癌症患者接种疫苗的疗效和副作用相关的现有数据。
